DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for euthyroid sick syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEuthyroid sick syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for euthyroid sick syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
thyroid hormone receptor alpha (THRA) — THRA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1-methylethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3ILZ · 1.85 Å · ligand {4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid (B72). Experimental structure, not a prediction.
What the evidence adds up to
A 2016 review states that euthyroid sick syndrome involves alterations in iodothyronine deiodinases, thyroid-stimulating hormone secretion, thyroid hormone binding to plasma protein, peripheral tissue transport of thyroid hormone, and thyroid hormone receptor activity. The syndrome is described as a complex mix of physiologic adaptation and pathologic response to acute illness, and the underlying cause has not been elucidated. The review notes that treatment with thyroid hormone to restore normal serum levels has been the focus of many clinical studies, but currently available data do not provide evidence of a clear benefit.
A 1991 journal article on the euthyroid sick syndrome contains no patient data, no sample sizes, and no treatment outcomes. A 2001 article on euthyroid sick syndrome in older people states that the term describes abnormalities in thyroid function tests in patients with systemic non-thyroid illness, that there is usually little clinical evidence of hypothyroidism despite these abnormalities, and that patients are generally considered to have altered thyroid hormone metabolism and to be euthyroid. No concrete numbers, survival rates, or response rates are reported in any of the three abstracts.
The evidence base consists entirely of narrative reviews. No randomised controlled trial data, no survival statistics, and no response rates are provided. What is missing is any prospective trial that tests thyroid hormone replacement against placebo in a defined patient population, with stratification by severity of illness and baseline thyroid function, and with adequate funding to detect a difference in clinical outcomes rather than just serum hormone levels.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Comprehensive physiology · 2016 · 162 citations
Euthyroid Sick Syndrome
AbstractIn this review, we discuss the characteristics, pathophysiology, and therapeutic implications of the euthyroid sick syndrome. Multiple mechanisms have been identified to contribute to the development of euthyroid sick syndrome, including alterations in the iodothyronine deiodinases, thyroid-stimulating hormone secretion, thyroid hormone binding to plasma protein, transport of thyroid hormone in peripheral tissues, and thyroid hormone receptor activity. The euthyroid sick syndrome appears to be a complex mix of physiologic adaptation and pathologic response to acute illness. The underlying cause for these alterations has not yet been elucidated. Treatment of the euthyroid sick syndrome with thyroid hormone to restore normal serum thyroid hormone levels in an effort to improve disease prognosis and outcomes continues to be a focus of many clinical studies, although currently available data do not provide evidence of a clear benefit of treatment.
AbstractJournal Article The Euthyroid Sick Syndrome Get access C. J. PEARCE C. J. PEARCE University Department of Chemical Pathology, Royal Liverpool HospitalLiverpool L7 8XP Search for other works by this author on: Oxford Academic PubMed Google Scholar Age and Ageing, Volume 20, Issue 3, May 1991, Pages 157–159, https://doi.org/10.1093/ageing/20.3.157 Published: 01 May 1991
Reviews in Clinical Gerontology · 2001 · 2 citations
Euthyroid sick syndrome in older people
AbstractThe term euthyroid sick syndrome (ESS) is used to describe abnormalities in thyroid function tests that are observed in patients with systemic non-thyroid illness. Despite these abnormalities, there is usually little clinical evidence of hypothyroidism. Patients with ESS are generally considered to have altered thyroid hormone metabolism and to be euthyroid.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
